Key facts

Active Substance
Levomilnacipran
Therapeutic area
Neurology
Decision number
P/0128/2015
PIP number
EMEA-001724-PIP01-14
Pharmaceutical form(s)
  • Prolonged-release capsule
  • Capsule (hard)
Condition(s) / indication(s)
Treatment of stroke
Route(s) of administration
Oral use
Contact for public enquiries

Pierre Fabre Medicament

France
Tel. +33 149108081

Decision type
RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)
Decision date

Decision

P/0128/2015: EMA decision of 5 June 2015 on the refusal of a product-specific waiver for levomilnacipran (EMEA-001724-PIP01-14)

How useful do you find this page?